Syndax Pharmaceuticals Management
Management criteria checks 1/4
Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 2.25 years. total yearly compensation is $9.13M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $1.16M. The average tenure of the management team and the board of directors is 1.9 years and 7.8 years respectively.
Key information
Michael Metzger
Chief executive officer
US$9.1m
Total compensation
CEO salary percentage | 7.4% |
CEO tenure | 2.3yrs |
CEO ownership | 0.06% |
Management average tenure | 1.9yrs |
Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Is Syndax Pharmaceuticals (NASDAQ:SNDX) Weighed On By Its Debt Load?
Jun 11Shareholders Would Not Be Objecting To Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Compensation And Here's Why
May 07The Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Has Gained 150%, So Why Not Pay It Some Attention?
Mar 15CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$9m | US$678k | -US$209m |
Sep 30 2023 | n/a | n/a | -US$176m |
Jun 30 2023 | n/a | n/a | -US$160m |
Mar 31 2023 | n/a | n/a | -US$153m |
Dec 31 2022 | US$4m | US$640k | -US$149m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | US$818k |
Mar 31 2022 | n/a | n/a | US$15m |
Dec 31 2021 | US$3m | US$594k | US$25m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$91m |
Mar 31 2021 | n/a | n/a | -US$86m |
Dec 31 2020 | US$2m | US$577k | -US$77m |
Sep 30 2020 | n/a | n/a | -US$71m |
Jun 30 2020 | n/a | n/a | -US$63m |
Mar 31 2020 | n/a | n/a | -US$61m |
Dec 31 2019 | US$3m | US$540k | -US$56m |
Sep 30 2019 | n/a | n/a | -US$61m |
Jun 30 2019 | n/a | n/a | -US$65m |
Mar 31 2019 | n/a | n/a | -US$69m |
Dec 31 2018 | US$2m | US$506k | -US$74m |
Sep 30 2018 | n/a | n/a | -US$74m |
Jun 30 2018 | n/a | n/a | -US$72m |
Mar 31 2018 | n/a | n/a | -US$67m |
Dec 31 2017 | US$1m | US$492k | -US$61m |
Compensation vs Market: Michael's total compensation ($USD9.13M) is above average for companies of similar size in the US market ($USD5.72M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Metzger (52 yo)
2.3yrs
Tenure
US$9,127,419
Compensation
Mr. Michael A. Metzger, M.B.A. serves as Chief Executive Officer at Syndax Pharmaceuticals, Inc since February 03, 2022 and has been its Director since July 4, 2019. He served as Senior Vice President and...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 2.3yrs | US$9.13m | 0.062% $ 1.2m | |
President | 1.1yrs | US$4.04m | 0.015% $ 288.3k | |
CFO, Treasurer & Chief Accounting Officer | 1.9yrs | US$2.83m | 0.017% $ 324.5k | |
Senior VP | 7.8yrs | US$2.59m | 0.051% $ 950.5k | |
Chief Medical Officer | 2.2yrs | US$2.81m | 0.043% $ 793.9k | |
Co-Founder & Chief Scientific Officer | 18.6yrs | no data | 0.00031% $ 5.8k | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Vice President of Investor Relations & Communications | 1.9yrs | no data | no data | |
Chief People Officer | less than a year | no data | no data | |
Member of Scientific Advisory Board & Chief Medical Officer | 1.4yrs | no data | no data |
1.9yrs
Average Tenure
54yo
Average Age
Experienced Management: SNDX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 4.8yrs | US$9.13m | 0.062% $ 1.2m | |
Co-Founder | 7.8yrs | no data | no data | |
Member of Scientific Advisory Board & Chief Medical Officer | 7.8yrs | no data | no data | |
Independent Director | 7.2yrs | US$581.02k | 0.038% $ 703.1k | |
Independent Director | 7.3yrs | US$575.59k | 0.038% $ 703.1k | |
Independent Chairman | 15.4yrs | US$1.10m | 0.017% $ 317.0k | |
Member of Scientific Advisory Board | 7.1yrs | US$23.05k | no data | |
Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
Director | 8.8yrs | US$30.91k | 0.021% $ 391.9k | |
Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
Member of Scientific Advisory Board | 8.4yrs | no data | no data |
7.8yrs
Average Tenure
63yo
Average Age
Experienced Board: SNDX's board of directors are considered experienced (7.8 years average tenure).